Le consortium Neu-vasc, dont le coordinateur est Jérôme Badaut, vient de recevoir un financement (1 014 748 Euros) par l’EraNet Neuron sur le mild-traumatic brain injury in pediatrics and Neurovascular dysfunctions :
Title: Neurovascular damage determines disease pathophysiology in pediatric mild traumatic brain injury: source of new biomarkers.
Coordinator : Dr Jerome Badaut, PhD, CNRS Research Director, Group Leader Brain Molecular Imaging, INCIA
Project Partners :
- Dr Nicola Marchi, PhD, CNRS CRCN, Group leader Cerebrovascular and Glia Research, IGF, INSERM-CNRS University of Montpellier
- Dr, Prof Inga K. Koerte, MD-PhD, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Ludwig-Maximilians-Universität (LMU) Munich
- Dr Roger Thompson, PhD, Hotchkiss Brain Institute, University of Calgary
- Dr Peter Filipcik, PhD, Institute of neuroimmunology, Slovak Academy of science, Bratislava
Ce consortium va permettre de renforcer les liens avec LMU (qui vient de signer un partnership avec l’université de Bordeaux) et HBI, Calgary qui est partenaire avec Bordeaux Neurocampus.
Traumatic Brain Injury (TBI), even mild (m)TBI, in pediatric populations induced long-term functional deficits for 30% of the patients, yet to date there are no good tools to identify these patients. Therefore, there is an urgent need to develop and validate new biomarkers for pediatric (p) mTBI. From the knowledge gathered in moderate/severe TBI, brain vasculature dysfunctions with, for example, bleeding and loss of cerebral blood flow (CBF) have been shown to be a negative prognostic factor for a good recovery. However, there is little known about cerebrovascular changes eliciting after pmTBI. The aim of the current project is therefore to validate the use of early CBF in patients to classify them. The project will also unravel the mechanisms resulting in these cerebrovascular changes in order to identify novel blood biomarkers such as miRNA aimed at prognosis of longterm functional deficits after pmTBI. This will be achieved by establishing a translational consortium (Neu-Vasc) of internationally recognized experts in the field of brain injury, the use of past data as well as generating new experimental data using state-of-the-art of clinical and preclinical techniques (from neuroimaging to the molecular level with the use of machine learning).